Pediatr Infect Dis J: cephalosporine-avithromycin therapy for the safety and effectiveness of concurrent urinary tract infections in children aged 3 months to 18 years

Cephalosporine-Avisin is effective and well tolerated in adults with complex urinary tract infections (cUTI), but has not been evaluated in children with cUTIthis single-blind, multi-center, active-control phase 2 study (NCT02497781) will be randomly enrolled in the cUTI children between 3 months and 18 years of age (3:1), intravenous (IV) cephalosporine-Avisininor or cephalosporine spore sporine for 72 hours, and then choose oral conversionThe total duration of treatment is 7-14 daysThe primary goal is to evaluate securitySecondary objectives include descriptive efficacy and pharmacokineticsA double-blind observer determines the causality and clinical outcome of adverse events (AE) until late follow-up (20-36 days after the last intravenous/oral treatment)results, a total of 95 children were given intravenous research drugs (cephalosporine-Avitrico, n s 67; cephalosporine, n s 28)The leading baseline Gram-negative urinary tract pathogen is Ecoli (92.2%)53.7% and 53.6% of the patients occurred in the aes of cephalosporine-Avibacterium and cephalosporine, respectivelySevere AE occurs in patients with 11.9% (cephalosporine-Avibacterium group) and 7.1% (cephalosporine group)One case of severe AE (cephalosporine-Avibacterium group) was thought to be drug-relatedIn the Microbiology Intent-Therapeutic Analysis group, both groups observed a favorable clinical response rate of 95% at the end of phase IV, with a duration of 88.9% (cephalosporine-Avimyosin group) and 82.6% (cephalosporine group) at the time of the cured trialAt the time of the curing trial, the patient's microbiological response rate was 79.6% (cephalosporine-Avisillin) and 60.9% (cephalosporine), respectively, the results show that cephalosporine-avithromycin is well tolerated in children with infectious uremia, its safety is consistent with that of adult spore infection patients and the individual use of cephalosporine, and appears to be effective in children with Gram-negative pathogen infectious uremia